Brought to you by:
Vein mapping rates show no sign of change two years after BEST-CLI, new study demonstrates
Vein mapping for lower extremity bypass in patients with chronic limb-threatening ischemia (CLTI) remains unchanged two years after the BEST-CLI, “revealing the difficulty in changing practice patterns based on new evidence,” according to the authors behind a new retrospective multicenter…
Designated multispecialty CLTI teams may help in amputation fight
Teams formally defined as specializing in chronic limb-threatening ischemia (CLTI) were associated with a decreased risk of major amputation among a subset of BEST-CLI trial sites, a paper recently published online ahead of print in the Journal of Vascular Surgery…
Analysis of BEST-CLI, PREVENT III reveals significant improvement in vein bypass outcomes over 20-year period
A post-hoc comparison of the BEST-CLI and PREVENT III multicenter, prospective, randomized controlled trials (RCTs) aimed at evaluating outcomes of vein bypass in chronic limb threatening ischemia (CLTI) patients over the past two decades found that they had “significantly improved”…
Cost-effectiveness outcomes defy expectations in latest BEST-CLI data drop
The open surgical approach will prove to be “slightly superior” to endovascular intervention in terms of cost per life year gained, while the latter will be slightly superior to open surgery with regard to cost per quality-adjusted life year gained,…
New study validates BEST-CLI trial results, ‘suggesting generalizability’
A new propensity-matched analysis of more than 1,100 lower extremity revascularization procedures carried out in patients with chronic limb-threatening ischemia (CLTI)—which aimed to help solve the puzzle of why the BEST-CLI trial did not lead to a pick-up in the…
SVS leadership and membership integral to ‘far-reaching’ BEST-CLI trial
Support from the Society for Vascular Surgery (SVS) and, later, funding from the SVS Foundation were integral to the BEST-CLI trial, said one of the landmark trial’s leaders. BEST-CLI sought to determine the best revascularization treatment strategy—surgical or endovascular—for patients…
BEST-CLI trial spline model analysis breaks new ground in assessing the impact of CKD severity on CLTI outcomes
A new analysis of the BEST-CLI trial has produced the first evidence-based glomerular filtration rate (eGFR) value—30 mL m2—as the cutoff below which patients with chronic limb-threatening ischemia (CLTI) experience significantly worse outcomes after revascularization regardless of the treatment modality…
BEST-CLI: Trial results endure in analysis of patients who presented with diabetes
Diabetes affects approximately 70% of patients with chronic limb-threatening ischemia (CLTI) and is associated with more severe presentation, driven mostly by higher rates of wounds and infections, according to a recently presented retrospective analysis of BEST-CLI randomized controlled trial data.…
The top 10 most popular Vascular Specialist stories of October 2024
In October, the most read stories from Vascular Specialist included a new leadership announcement from the American College of Surgeons (ACS); study results examining a potential link between strenuous physical activity and increased venous thromboembolism (VTE) risk in men; the publication…
Smoking: BEST-CLI trial points to protective effect against MALE in those undergoing open bypass over endovascular intervention
An analysis of the BEST-CLI randomized controlled trial (RCT) found that smokers with chronic limb-threatening ischemia (CLTI) should be preferentially treated with open bypass over endovascular intervention. Researchers from the University of California San Diego (UCSD) looked at BEST-CLI patients…